IE000OZRGNV6 - Common Stock
NABRIVA THERAPEUTICS PLC
NASDAQ:NBRV (7/31/2023, 7:00:01 PM)
After market: 1.3986 -0.02 (-1.51%)1.42
0 (0%)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The firm is engaged in the commercialization, research and development of novel anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.
NABRIVA THERAPEUTICS PLC
Alexandra House Office 225/227,, The Sweepstakes,, Ballsbridge
DUBLIN 19406
P: 3536108166640.0
CEO: Theodore Schroeder
Employees: 39
Website: https://www.nabriva.com/
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!
Although the internet encourages you to buy the red ink, sometimes you should consider stocks to sell as just that.
Nabriva Therapeutics (NBRV) and Merck (MRK) have ended the deal for U.S. distribution of Sivextro, an antibacterial indicated for certain skin and skin infections. Read the full story here.
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- ...
Ireland-based pharma Nabriva Therapeutics (NBRV) rose ~15% on Monday morning after announcing results from a Phase 1 trial for its antibiotic Xenleta in adults with cystic...
Here you can normally see the latest stock twits on NBRV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: